Secukinumab

• Fully humanized IgG1 κ monoclonal antibody that targets interleukin 17 (IL-17)
• Indicated for psoriasis, psoriatic arthritis, and ankylosing spondylitis
• Used off-label for rheumatoid arthritis, lupus, familial Mediterranean fever, and TRAPS, as well as hidradenitis suppurativa, pityriasis rubra pilaris, refractory spontaneous chronic urticaria, papulopustular rosacea, ABCA12 deficiency-related ichthyosis, and Behçet disease
• Adverse effects include nasopharyngitis, URTI, diarrhea